SCHEMBL4866652

SCHEMBL4866652

CCCN(CCCCN1CCCCC1=O)C(C)Cc1ccc(C(C)(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
NPC1 O15118 1/20 0.41
SIGMAR1 Q99720 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MITF O75030 1/20 0.36
RAB9A P51151 1/20 0.36
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
ACHE P22303 1/20 0.34
ADRA1B P35368 2/20 0.33
SOAT2 O75908 1/20 0.33
SOAT1 P35610 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4875410 0.93 MEN1 (0.41) MEN1KMT2ANPC1SIGMAR1SMN1; SMN2
SCHEMBL4875568 0.92 MEN1 (0.41) MEN1KMT2ANPC1SIGMAR1SMN1; SMN2
SCHEMBL4868912 0.88 MEN1 (0.33) MEN1KMT2ANPC1TP53TSHR
SCHEMBL4875539 0.88 ADAMTS5 (0.40) KMT2ARAB9AACHEADRA1BLMNA
SCHEMBL4874172 0.86 SLC6A4 (0.40) MEN1KMT2ANPC1RAB9AADRA1B
SCHEMBL4870520 0.85 TP53 (0.32) SIGMAR1TP53TSHR
SCHEMBL4876330 0.85 POLB (0.37) MEN1KMT2ARAB9ATSHRSOAT2
SCHEMBL4866709 0.84 PARP1 (0.43) KMT2ANPC1SMN1; SMN2MITFRAB9A
SCHEMBL4866722 0.84 POLB (0.36) MEN1KMT2ARAB9ATSHRSOAT2
SCHEMBL27577614 0.83 L3MBTL1 (0.40) MEN1KMT2ASIGMAR1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7361648-B2 Heterocyclylakylamines as muscarinic receptor antagonists ROCHE PALO ALTO LLC (US) 2008-04-22 US disclosed
US-20060287293-A1 Heterocyclylalkylamines as muscarinic receptor antagonists ROCHE PALO ALTO LLC 2006-12-21 US disclosed
US-7094778-B2 Heterocyclylalkylamines as muscarinic receptor antagonists SYNTEX (U.S.A.) LLC (US) 2006-08-22 US disclosed
EP-1289965-B1 SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2005-10-26 EP disclosed
US-20040087581-A1 Heterocyclylalkylamines as muscarinic receptor antagonists DVORAK CHARLES ALOIS (US) 2004-05-06 US disclosed
US-6667301-B2 Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders SYNTEX (U.S.A.) LLC 2003-12-23 US disclosed
US-20020004501-A1 Heterocyclylalkylamines as muscarinic receptor antagonists SYNTEX (U.S.A.) LLC 2002-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287293-A1 Heterocyclylalkylamines as muscarinic receptor antagonists CHRM5, CHRM2, CHRM3 MEN1 1954/4885KMT2A 1941/4885NPC1 1987/4885
US-20020004501-A1 Heterocyclylalkylamines as muscarinic receptor antagonists CHRM5, CHRM2, CHRM1 MEN1 1892/4885KMT2A 2014/4885NPC1 1483/4885
US-20040087581-A1 Heterocyclylalkylamines as muscarinic receptor antagonists CHRM5, CHRM2, CHRM1 MEN1 1892/4885KMT2A 2014/4885NPC1 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.